KINARX
KinaRx LLC is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of Acute myeloid leukemia, with an emphasis on the treatment of drug resistant tumors.
KINARX
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
West Lafayette, Indiana, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
2.13 M USD
Current Employees Featured
Founder
Investors List
National Cancer Institute
National Cancer Institute investment in Grant - KinaRx
More informations about "KinaRx"
KinaRx – A biotech company developing novel kinase inhibitors …
KinaRx Changing the drug discovery paradigm to anticipate cancer patients’ needs with novel classes of kinase inhibitors. Learn More News Company Overview Early stage biotechnology …See details»
Company Overview - KinaRx
Company Overview Early stage biotechnology company developing novel kinase inhibitors for cancer. Inspired by the desire to treat patients we are relentlessly focused on developing the …See details»
KinaRx - Crunchbase Company Profile & Funding
Organization. KinaRx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. KinaRx is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of …See details»
KinaRx Company Profile 2024: Valuation, Funding & Investors
KinaRx General Information Description. Operator of a biotechnology company intended to develop novel kinase inhibitors for treating cancer patients. The company's technology aims at …See details»
Our Science – KinaRx
Our Science A rapid discovery platform Identify KIPS (Kinase Privileged Scaffolds) and use Multicomponent rapid chemical synthesis reactions to generate novel highly effective kinase inhibitors. Learn More Tailored drug …See details»
KinaRx, LLC - VentureRadar
KinaRx is a biotechnology company developing novel kinase inhibitors for cancer. Our proprietary technology, generates unique compounds potently active against protein kinases with a focus …See details»
KinaRx - Funding, Financials, Valuation & Investors - Crunchbase
KinaRx is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of Acute myeloid leukemia. Search Crunchbase. ... How much funding has this organization …See details»
KinaRX LLC - Drug pipelines, Patents, Clinical trials - Synapse
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into …See details»
KinaRx - Tech Stack, Apps, Patents & Trademarks - Crunchbase
KinaRx is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of Acute myeloid leukemia. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
KinaRx, LLC Company Profile | Rockville, MD - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for KinaRx, LLC of Rockville, MD. Get the latest business insights from Dun & Bradstreet.See details»
Kinarx - Products, Competitors, Financials, Employees, …
Kinarx is an early-stage biotechnology company focused on developing kinase inhibitors for cancer treatment. Use the CB Insights Platform to explore Kinarx's full profile. Kinarx - …See details»
KinaRx receives SBIR grant to speed up clinical trials for AML and ...
Jun 3, 2020 A $1,999,998 SBIR Phase I/II grant from the National Institute of Cancer to KinaRx LLC, a Purdue University-affiliated startup, will help fast-track to human trials a novel platform …See details»
KinaRx - Crunchbase
KinaRx is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of Acute myeloid leukemia. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
KinaRX | CipherBio
Explore KinaRX's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
HSN608 - Drug Targets, Indications, Patents - Synapse - Patsnap
RET rearrangement is a recently identified oncogenic mutation in lung adenocarcinoma (LADC) that accounts for approximately 2% of all NSCLCs. More than six fusion partners have been …See details»
Pipeline - KinaRx
Pipeline FLT3 mutant AML Activating mutations in FLT3 are found in 30% of Acute Myeloid Leukemia (AML) and associated with poor prognosis. Approved FLT3 inhibitors show clinical …See details»
Kinark Child and Family Services
Kinark Autism Services provides high quality, evidence-based services to children and youth (ages 2-18) with Autism Spectrum Disorder (ASD) and their families. For families registered in …See details»
KinaRx - Contacts, Employees, Board Members, Advisors & Alumni …
KinaRx is a biotech firm focuses on the development of novel kinase inhibitors for the treatment of Acute myeloid leukemia. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
The Kinark Foundation
The Kinark Foundation offers hope and help by raising funds and awareness to support the mission of Kinark – helping children and youth with complex needs achieve better life …See details»
Publications – KinaRx
Publications Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach Xiaochu Ma, Jie Zhou, Changhao Wang, Brandon Carter-Cooper, …See details»